Houdini Bio: tackling the gene-silencing barrier in genetic medicines

Genetic medicines have advanced rapidly in recent years, but delivering therapeutic DNA to the right cell is only part of the challenge.

Once inside a cell, introduced DNA can be recognised as foreign genetic material. The cell's natural defence mechanisms can then act to silence it, reducing the amount of therapeutic protein produced and potentially limiting how long a treatment remains effective.

This is the biological problem that Houdini Bio is seeking to solve.

The Cambridge-based biotech is developing technology that combines synthetic biology, DNA engineering and artificial intelligence to redesign therapeutic DNA so that it can evade cellular gene-silencing mechanisms while retaining its intended biological function.

The company sees this as a new layer of therapeutic DNA design that could sit alongside existing approaches to delivery, targeting and manufacturing.

Cells switching genetic medicines off is the challenge

Many genetic medicines work by introducing new genetic instructions into cells. Those instructions can then be used to produce a therapeutic protein or otherwise alter cellular behaviour.

But cells have evolved sophisticated mechanisms for recognising and suppressing foreign genetic material.

One of the mechanisms Houdini Bio is focused on is the Human Silencing Hub, or HUSH complex, which plays a role in the repression of foreign and repetitive DNA.

The company's technology is based on research into how HUSH recognises and silences DNA. Houdini Bio co-founder and CEO Jonathan Cohen-Gold developed the foundational work during his PhD at the University of Cambridge, building on the discovery of the HUSH complex by Professor Paul Lehner.

Rather than accepting gene silencing as an unavoidable consequence of introducing therapeutic DNA, developers can engineer the DNA sequence itself to reduce the likelihood of it being switched off.

This gives developers another potential variable to work with when designing genetic medicines. The DNA can be designed with the cell's defence mechanisms in mind from the outset.

ARCANA: engineering DNA to escape silencing

Houdini Bio's technology platform, ARCANA, uses machine learning alongside the company's understanding of the underlying biology to identify sequence features associated with cellular gene silencing.

The platform is designed to help predict which DNA sequences are more likely to remain active, and then engineer therapeutic constructs to reduce the signals that trigger cellular repression.

The company describes the approach as modality agnostic, meaning it is intended to work across different therapeutic payloads, delivery systems and target cell types.

That could give the technology potential applications across a range of genetic medicine modalities, including gene therapies and cell therapies.

Houdini Bio also believes that improving the persistence of therapeutic DNA could have implications beyond efficacy. If a medicine can produce the required biological effect from a smaller amount of therapeutic material, there could be potential benefits around dosing, manufacturing requirements and the overall economics of treatment.

These remain development-stage opportunities rather than established clinical outcomes, but they help explain why controlling therapeutic DNA expression is an area of growing interest as genetic medicines become more complex.

From discovery to engineering

A key part of Houdini Bio's proposition is moving away from a largely experimental approach to DNA optimisation.

Today, developers can screen large numbers of genetic constructs to identify versions that perform better. Houdini Bio is attempting to make this process more predictable by identifying the underlying biological rules that determine whether therapeutic DNA is silenced.

The company says its platform has demonstrated substantially increased expression in validated models, including more than 10-fold higher gene expression compared with current state-of-the-art approaches in its own testing.

These findings are company-reported preclinical results and will need to translate into independent validation and ultimately clinical performance before their therapeutic significance can be established.

The underlying concept is that if DNA sequence can be engineered to work with, rather than against, the cell's regulatory machinery, it could become another controllable parameter in the design of genetic medicines.

Houdini Bio and CureAge Therapeutics

That concept is now being explored through a new collaboration with CureAge Therapeutics.

CureAge is developing DNA-based genetic medicines for peripheral nerve diseases, initially focusing on Neurofibromatosis type 1 (NF1). Its approach combines therapeutic DNA with targeted lipid nanoparticle (LNP) delivery, with the aim of developing targeted, redosable and durable treatments for chronic disease.

The collaboration addresses a challenge that sits directly downstream of delivery.

For a DNA medicine to work, the therapeutic DNA needs to reach the appropriate cells and ultimately the nucleus. But successful delivery does not guarantee sustained expression. Once inside the cell, the DNA can still be recognised as foreign and subjected to gene-silencing mechanisms.

CureAge brings expertise in disease biology, therapeutic DNA design and targeted LNP delivery, while Houdini Bio brings its work in DNA engineering and gene silencing. Together, the companies will explore strategies intended to support robust and sustained activity of CureAge's therapeutic DNA constructs.

For CureAge, the collaboration forms part of its work towards developing genetic medicines for peripheral nerve diseases, starting with NF1.

For Houdini Bio, it provides an opportunity to apply its anti-silencing technology within a defined therapeutic programme and test whether engineering the DNA itself can complement advances in non-viral delivery.

A connection through Deep Science Ventures

Houdini Bio's development also reflects the role of Deep Science Ventures (DSV) in creating and backing companies around emerging scientific technologies.

DSV lists Houdini Bio in its portfolio as a pre-seed pharmaceutical company, describing the company's opportunity as addressing an "invisible ceiling" created by cellular gene silencing. Its portfolio description highlights ARCANA as an AI-powered platform for decoding and engineering routes around cellular silencing while preserving biological function.

DSV also participated in Houdini Bio's pre-seed funding, alongside SCVC and Cambridge Enterprise Ventures. The company has said the funding has supported rapid validation of its technology and the development of partnerships with pharmaceutical companies and other genetic medicine developers.

The DSV connection is particularly interesting in the context of the CureAge partnership. Both companies sit within the DSV ecosystem, creating a link between two ventures approaching genetic medicine from complementary directions.

What comes next for Houdini Bio?

Houdini Bio is trying to make therapeutic DNA more predictable, durable and engineerable.

The company's thesis is that improving genetic medicines will require more than better delivery systems. Developers also need greater control over what happens to therapeutic DNA once it reaches the cell.

By combining biological understanding of gene silencing with machine-learning-driven DNA design, Houdini Bio is attempting to turn that previously difficult-to-control behaviour into something that can be engineered.

The CureAge collaboration represents an early test of that proposition in a real therapeutic development context.

As genetic medicines move towards increasingly sophisticated DNA constructs, non-viral delivery systems and applications across chronic diseases, the ability to control how long therapeutic DNA remains active could become an increasingly important part of the drug design process.

For Houdini Bio, the challenge now is to demonstrate that its understanding of cellular gene silencing can consistently translate into better-performing medicines and ultimately help push genetic therapies beyond the biological ceiling it has identified.